This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
Coming into 2020, Moderna Inc (NASDAQ: MRNA) was a $6.5 billion biotech with the goal of using messenger RNA (mRNA) — the molecule that tells cells what proteins to make — to fight and prevent disease. Not much was known about the company’s technology or even the diseases its drugs would target, but that changed in 2020 as the company became one of the leaders in the fight against COVID-19.
A breakout year
Moderna’s stock rose 434% during 2020, but that number doesn’t capture how eventful the year was, or the ups and downs shareholders experienced. After receiving funding from the Coalition for Epidemic Preparedness Innovations in late January, the company worked with the National Institute of Allergy and Infectious Diseases to deliver a COVID-19 vaccine candidate a month later.
Positive phase 1 data were released in mid-May, and management promptly raised $1.34 billion through a secondary share offering. On 30 November, the company provided analysis from phase 3 data showing its vaccine was 94.1% effective at preventing COVID-19. Three weeks later, on 18 December, the Food and Drug Administration (FDA) granted emergency use authorization (EUA).
Although the stock’s rise has been tremendous, its overall uneven progress offers a lesson in perseverance for shareholders. While everyone would welcome a more than 400% rise in a stock, holders had to endure a 25% sell-off (or more) four different times.
Looking ahead, the company is well positioned for the future. Moderna had $3.3 billion in cash and investments on its balance sheet as of 30 September and recently increased the number of COVID-19 vaccine doses it expects to make in 2021 from 500 million to 600 million. The company has already supplied 18 million of an agreed-upon 200 million doses to the US Government and has additional deals with Canada, Israel, South Korea, and the European Commission, among other recipients . Despite this good news already priced into shares, the company has said it could produce as many as a billion doses this year. If so, last year’s gains in the share price could continue through 2021.
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of June 30th
More reading
- The worst mistake Moderna investors can make right now
- Why Moderna stock fell 32% in December
- Moderna’s stock has surged 488% in 2020: Is it a buy for 2021?
- Here are the US shares ASX investors are buying
- How the 21st century actually started in 2020
Jason Hawthorne has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
The post How MRNA stock performed in 2020 appeared first on The Motley Fool Australia.
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
from The Motley Fool Australia https://ift.tt/2Xe1Jpr
Leave a Reply